Tremfaya, Geselcumab 100 mg - 1 injection

Tremfaya, Geselcumab 100 mg - 1 injection

Description:

Tremfaya (guselkumab) 100 mg is a prescription biologic medicine supplied as a single pre-filled injection. It is a human monoclonal antibody that selectively targets interleukin-23 (IL-23), a key cytokine involved in inflammatory and immune-mediated diseases. Tremfaya is used under specialist medical supervision to treat certain chronic inflammatory conditions, helping to control symptoms, improve skin and joint health, and enhance overall quality of life. This product is intended for use by adults only and must be administered according to a physician’s instructions.

Indications:

• Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy (as per typical guselkumab indications; confirm exact indication with prescribing information).
• May be used to reduce redness, scaling, and thickness of psoriatic plaques and improve skin clearance.
• Improves psoriasis-related symptoms such as itching, burning, and discomfort.
• May be indicated for psoriatic arthritis in adults to reduce joint pain, swelling, and stiffness (depending on local approved label; confirm with physician).

Active Ingredients / Key Components:

• Guselkumab – 100 mg per injection (monoclonal antibody targeting il-23).
• Excipients: Specific inactive ingredients (such as stabilizers, buffers, and preservatives) are not provided in the available product information. Please refer to the official package insert for the complete excipient list and concentrations.

Dosage & Administration / How to Use:

• Tremfaya (guselkumab) 100 mg is for subcutaneous injection only and must be used exactly as prescribed by a dermatologist or rheumatologist.
• Typical adult dosing for plaque psoriasis (for reference only – always follow your doctor’s regimen): an initial 100 mg injection at week 0, a second 100 mg injection at week 4, then 100 mg every 8 weeks thereafter. Your doctor may adjust the schedule based on your condition and response.
• Administration sites usually include the thigh, abdomen (avoiding a 5 cm area around the navel), or upper arm. Do not inject into areas that are tender, bruised, red, hardened, or affected by active psoriasis.
• The injection should be given by a healthcare professional or by the patient/caregiver only after proper training in subcutaneous injection technique.
• Do not shake the pre-filled syringe or device. Inspect the solution visually for particulate matter or discoloration before use; do not use if the solution is cloudy, discolored, or contains particles.
• Do not change the dose or dosing schedule without consulting your doctor. If a dose is missed, contact your healthcare provider for instructions; do not double the dose to make up for a missed injection.
• This medicine is not taken with food or drink, as it is administered by injection only.

Clinical Benefits:

• Helps achieve significant skin clearance in moderate to severe plaque psoriasis by selectively inhibiting il-23.
• Reduces redness, scaling, and thickness of psoriatic plaques, leading to smoother and healthier-looking skin.
• May improve joint symptoms in psoriatic arthritis, including pain, swelling, and stiffness, thereby supporting better mobility and function (where indicated).
• Provides long-term disease control with maintenance dosing, which may reduce flare-ups and improve quality of life.
• Targeted mechanism of action focuses on a specific pathway in the immune system, which may offer an improved benefit–risk profile compared with some traditional systemic therapies.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to guselkumab or any of the excipients in the formulation.
• Use with caution in patients with active, chronic, or recurrent infections. Do not use in patients with clinically significant active infections until the infection is controlled.
• Before starting Tremfaya, patients should be evaluated for tuberculosis (tb). Treatment of latent tb should be initiated prior to therapy if indicated.
• May increase the risk of infections, including upper respiratory tract infections. Monitor patients closely for signs and symptoms of infection during and after treatment.
• Use with caution in patients with a history of inflammatory bowel disease; new or worsening symptoms should be reported to the doctor immediately.
• Immunizations: Live vaccines should be avoided during treatment and for a period before and after therapy as advised by your doctor. Inform your healthcare provider about all recent or planned vaccinations.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. The safety of guselkumab in pregnancy and lactation is not fully established; your doctor will assess potential benefits and risks.
• Inform your doctor about all medications, including other biologics, immunosuppressants, or systemic therapies for psoriasis or arthritis, to avoid potential interactions or additive immunosuppression.
• Not intended for use in children unless specifically prescribed by a pediatric specialist.
• Keep out of reach of children.

Side Effects:

• Common side effects may include upper respiratory tract infections (such as sore throat, runny nose), headache, injection site reactions (redness, pain, swelling), and gastrointestinal discomfort. These are usually mild to moderate.
• Less common but potentially serious side effects include serious infections, hypersensitivity or allergic reactions (rash, itching, swelling of the face or throat, difficulty breathing), and possible worsening of inflammatory bowel disease. Seek immediate medical attention if severe allergic symptoms or signs of serious infection (fever, persistent cough, shortness of breath, weight loss, night sweats) occur.
• If you experience any unusual symptoms, persistent side effects, or worsening of your condition, contact your doctor promptly.

Storage Instructions:

Store Tremfaya (guselkumab) injection in a refrigerator at 2–8°c. Do not freeze. Keep the pre-filled syringe or device in the original carton to protect it from light. Do not shake. If needed, the product may be kept at room temperature for a limited time as specified in the official package insert; once removed from refrigeration and kept at room temperature, it should not be returned to the refrigerator. Keep out of reach of children.

Specifications:

• Form: single-dose pre-filled injection for subcutaneous use.
• Strength: 100 mg guselkumab per injection.
• Pack size: 1 injection (single-use).
• Intended user group: adults, under prescription and supervision of a qualified healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.